These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 28042719)

  • 21. Impact of patient and treatment characteristics on glycemic control and hypoglycemia in patients with type 2 diabetes initiated to insulin glargine or NPH: A post hoc, pooled, patient-level analysis of 6 randomized controlled trials.
    Porcellati F; Lin J; Lucidi P; Bolli GB; Fanelli CG
    Medicine (Baltimore); 2017 Feb; 96(5):e6022. PubMed ID: 28151905
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Beyond the era of NPH insulin--long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application.
    Owens DR; Bolli GB
    Diabetes Technol Ther; 2008 Oct; 10(5):333-49. PubMed ID: 18715209
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is insulin detemir able to favor a lower variability in the action of injected insulin in diabetic subjects?
    Valensi P; Cosson E
    Diabetes Metab; 2005 Sep; 31(4 Pt 2):4S34-4S39. PubMed ID: 16389896
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of the efficacy and safety of insulin glargine and insulin detemir with NPH insulin in children and adolescents with type 1 diabetes mellitus receiving intensive insulin therapy.
    Dündar BN; Dündar N; Eren E
    J Clin Res Pediatr Endocrinol; 2009; 1(4):181-7. PubMed ID: 21274293
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A patient centred approach to basal insulin choice for the management of type 2 diabetes mellitus.
    Kalra S; Gupta Y
    J Pak Med Assoc; 2016 Mar; 66(3):360-1. PubMed ID: 26968297
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [POET2 registry: Comparison of annual direct medical costs of treating type 2 diabetes after addition of insulin NPH or insulin glargine to oral antidiabetic therapy in the Czech Republic].
    Kvapil M; Žďarská DJ; Suchopár J; Prokeš M; Brož J
    Vnitr Lek; 2015 Jan; 61(1):24-32. PubMed ID: 25693613
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparison of intermediate and long-acting insulins in people with type 2 diabetes starting insulin: an observational database study.
    Gordon J; Pockett RD; Tetlow AP; McEwan P; Home PD
    Int J Clin Pract; 2010 Nov; 64(12):1609-18. PubMed ID: 20946269
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential effects of adiposity on pharmacodynamics of basal insulins NPH, glargine, and detemir in type 2 diabetes mellitus.
    Porcellati F; Lucidi P; Rossetti P; Candeloro P; Andreoli AM; Marzotti S; Cioli P; Bolli GB; Fanelli CG
    Diabetes Care; 2011 Dec; 34(12):2521-3. PubMed ID: 21972412
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety among second-generation and other basal insulins in adult patients with type 1 diabetes: a systematic review and network meta-analysis.
    Martin ; Zhou Y; Takagi T; Tian YS
    Naunyn Schmiedebergs Arch Pharmacol; 2021 Oct; 394(10):2091-2101. PubMed ID: 34319421
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy.
    Hermansen K; Madsbad S; Perrild H; Kristensen A; Axelsen M
    Diabetes Care; 2001 Feb; 24(2):296-301. PubMed ID: 11213882
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics and pharmacodynamics of therapeutic doses of basal insulins NPH, glargine, and detemir after 1 week of daily administration at bedtime in type 2 diabetic subjects: a randomized cross-over study.
    Lucidi P; Porcellati F; Rossetti P; Candeloro P; Cioli P; Marzotti S; Andreoli AM; Fede R; Bolli GB; Fanelli CG
    Diabetes Care; 2011 Jun; 34(6):1312-4. PubMed ID: 21498786
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-Term Use of Long-Acting Insulin Analogs and Breast Cancer Incidence in Women With Type 2 Diabetes.
    Wu JW; Azoulay L; Majdan A; Boivin JF; Pollak M; Suissa S
    J Clin Oncol; 2017 Nov; 35(32):3647-3653. PubMed ID: 28953430
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: Evidence from a long-term controlled trial.
    Rosenstock J; Fonseca V; Schinzel S; Dain MP; Mullins P; Riddle M
    J Diabetes Complications; 2014; 28(5):742-9. PubMed ID: 24856612
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized clinical trial of the efficacy and safety of insulin glargine vs. NPH insulin as basal insulin for the treatment of glucocorticoid induced hyperglycemia using continuous glucose monitoring in hospitalized patients with type 2 diabetes and respiratory disease.
    Ruiz de Adana MS; Colomo N; Maldonado-Araque C; Fontalba MI; Linares F; García-Torres F; Fernández R; Bautista C; Olveira G; de la Cruz JL; Rojo-Martínez G; Valdés S
    Diabetes Res Clin Pract; 2015 Nov; 110(2):158-65. PubMed ID: 26474657
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of basal insulin from a US health system perspective: comparative analyses of detemir, glargine, and NPH.
    Valentine WJ; Palmer AJ; Erny-Albrecht KM; Ray JA; Cobden D; Foos V; Lurati FM; Roze S
    Adv Ther; 2006; 23(2):191-207. PubMed ID: 16751153
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia.
    Davies MJ; Derezinski T; Pedersen CB; Clauson P
    Diabetes Technol Ther; 2008 Aug; 10(4):273-7. PubMed ID: 18715200
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-acting insulin analogues and diabetic retinopathy: a retrospective cohort study.
    Lin JC; Shau WY; Lai MS
    Clin Ther; 2014 Sep; 36(9):1255-68. PubMed ID: 25082730
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment persistence in the use of basal insulins in Poland and Germany
.
    Rathmann W; Czech M; Franek E; Kostev K
    Int J Clin Pharmacol Ther; 2017 Feb; 55(2):119-125. PubMed ID: 27879196
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized trial comparing the rate of hypoglycemia--assessed using continuous glucose monitoring--in 125 preschool children with type 1 diabetes treated with insulin glargine or NPH insulin (the PRESCHOOL study).
    Danne T; Philotheou A; Goldman D; Guo X; Ping L; Cali A; Johnston P
    Pediatr Diabetes; 2013 Dec; 14(8):593-601. PubMed ID: 23730996
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The efficacy of insulin degludec and insulin glargine over NPH insulin among toddlers and preschoolers with type 1 diabetes using glycemic variability and time in range.
    Elhabashy SA; Sakr EM; Salah NY
    Eur J Pediatr; 2023 Apr; 182(4):1857-1868. PubMed ID: 36800034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.